within Pharmacolibrary.Drugs.D_Dermatologicals.D06A_AntibioticsForTopicalUse.D06AX02_Chloramphenicol;

model Chloramphenicol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.0766666666666665e-05,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.0005,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Chloramphenicol</td></tr><tr><td>ATC code:</td><td>D06AX02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>17.8</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Chloramphenicol is a broad-spectrum antibiotic effective against a variety of Gram-positive and Gram-negative bacteria. It is used for the treatment of serious infections such as typhoid fever, meningitis, and rickettsial diseases, but its use has declined due to serious adverse effects (notably aplastic anemia). It is not a first-line antibiotic in most countries today and is restricted for specific indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral and intravenous administration.</p><h4>References</h4><ol><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=\"https://doi.org/10.1007/s40272-013-0017-5\">10.1007/s40272-013-0017-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529866/\">https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Zayyad, H, et al., &amp; Paul, M (2017). Revival of old antibiotics: needs, the state of evidence and expectations. <i>International journal of antimicrobial agents</i> 49(5) 536–541. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2016.11.021\">10.1016/j.ijantimicag.2016.11.021</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28162982/\">https://pubmed.ncbi.nlm.nih.gov/28162982</a></p></li><li><p>Ogutu, BR, et al., &amp; Kokwaro, GO (2002). Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. <i>British journal of clinical pharmacology</i> 54(6) 635–642. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.2002.01689.x\">10.1046/j.1365-2125.2002.01689.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12492612/\">https://pubmed.ncbi.nlm.nih.gov/12492612</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D06AX02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Chloramphenicol;
